Towards Healthcare
Blood Product Market Size, Material Cost & Supply Chain

Blood Product Market Size to Boom USD 59.89 Billion by 2034

The blood product market is booming, supplying vital components like whole blood, RBCs, WBCs, plasma, and platelets for surgeries, accidents, and medical treatments. Recent funding includes a $5M grant from Australia's NHMRC for Blood Synergy and a $5M seed round for Safi Biotherapeutics. Notably, high-income nations account for 40% of global blood donations.

Blood Product Market Companies, Volume and Stake Analysis

The global blood product market was estimated at US$ 36.52 billion in 2023 and is projected to grow to US$ 59.89 billion by 2034, rising at a compound annual growth rate (CAGR) of 4.6% from 2024 to 2034. The demand for blood and blood products is high due to their usage during surgeries, emergency situations, blood-related health issues, and many more health problems.

Blood Product Market Revenue 2023 - 2034

Unlock Infinite Advantages: Subscribe to Annual Membership

Market Overview

The blood product market is responsible for collecting, separating, storing, and distributing various blood products. These include whole blood, RBCs, WBCs, plasma, and platelets. The market is growing strongly because whole blood or components derived from blood are used during surgery, accidents, blood loss, blood cancer, or any particular health condition. Red blood cells are used for anemia, platelets for cancer treatment, plasma for trauma, shock, and burn, cryo for preventing and controlling bleeding, and WBCs for immunity.

  • In October 2024, the $5 million AUD grant that Australia's National Health and Medical Research Council (NHMRC) recently gave to the Blood Synergy research program is the first time that this funding has been utilized to expand an already-existing project.
  • In September 2024, in addition to the more than $15 million in investment that the U.S. Department of Defense has already provided, Safi Biotherapeutics, the pioneer in the creation of manufactured red blood cells (mRBCs) as a substitute for donor blood transfusions, announced a $5 million seed round headed by J2 Ventures.
  • In May 2023, with $50 million in hand from the innovative York Blood Center, NYBC Ventures was announced as one of the first venture firms to concentrate only on developing innovative blood and cell-based medicines.
  • 40% of the 118.5 million blood donations that are collected worldwide take place in high-income nations, which are home to sixteen percent of the world's population. A total of 106 million contributions have been reported by 13,300 blood clinics throughout 169 countries.

Blood Product Market is Growing Due to Cancer

Since millions of new cases of cancer are identified each year, cancer is becoming a bigger global problem. According to research on 29 diseases in 204 nations, the total cost of cancer to the world economy is predicted to exceed 25.2 trillion international dollars between 2020 and 2050. About half of it will be spent on five different forms of cancer. Because platelet counts drastically decline after cancer therapy and platelets are transfused to minimize bleeding issues, platelet transfusion is an essential and frequently required part of cancer management.

Market Challenge: Lack of Donor

Blood donations are usually made via free campaigns, and many people are not willing to donate blood, which becomes a growth barrier for the blood product market. The number of donors is reduced even more when people are unable to donate blood due to health issues like HIV, cancer, sickle cell, anemia, or any other disease. Apart from this, many people, especially in rural areas, are not aware of such practices or refrain from donating blood due to different beliefs.

Regional Insights

North America dominated the blood product market in 2023.

Many factors contribute to the growth of the market in North America. People often participate in blood donation campaigns; there is a huge presence of blood donation centers, and governments make continuous efforts to create awareness and develop better facilities for blood donation, component separation, and storage.

The U.S. dominated the blood product market in North America due to continuous efforts taken by the government, NGPs, public & private organizations, and other key stakeholders.

For instance,

  • Every two seconds, someone in the United States requires platelets or blood. In the United States, an estimated 6.8 million individuals give blood annually. The United States collects 13.6 million units of red blood cells and whole blood annually.

Every year, around 16 million blood components are transfused in the United States. There are 90,000 to 100,000 cases of sickle cell disease in the United States. The condition affects about 1,000 newborns annually. People with sickle cell disease may need blood transfusions for the rest of their lives. In 2023, about 1.9 million individuals are anticipated to receive a cancer diagnosis, according to the American Cancer Society. During their chemotherapy treatment, many patients may require blood transfusions on a regular basis.

Asia Pacific is expected to grow at the fastest rate during the forecast period.

The blood product market is growing strongly in Asia Pacific, mainly due to the growing population. A large population increases the number of people in need of blood or blood products. In addition, governments are also making efforts to increase blood donation and increase awareness about blood donation.

Every two seconds, there is a need for blood transfusions in India. An average of 14.6 million transfusions of blood are required annually. There were 4153 authorized blood banks (also known as blood centers) in the nation as of November 30, 2023; 1266 of them were government-affiliated, while the remaining 2887 were private. 5,897,452 blood units have been collected by the MoHFW as of October 2024, and 5,899,116 donors have signed up on the website.

Segmental Insights

By product type, the red blood cells (RBCs) segment dominated the blood product market and is estimated to grow at the fastest rate during the forecast period. The blood component that is transfused most frequently is red blood cells. Individuals who suffer from acute blood loss due to trauma or chronic anemia brought on by renal failure or gastrointestinal bleeding benefit the most from obtaining red blood cells.

By end-use, the blood station segment held the largest share of the market. The segment is dominating due to the growing number of blood stations worldwide. These stations have made blood collection, storage, and transfer easy. A large population visits blood stations for donation, and the collected blood is further transferred to hospitals, ambulatory centers, and clinics.

The hospital segment is estimated to grow rapidly in the blood product market during the forecast period. Hospitals are the major users of blood and blood products for treating anemia, cancer, or any other health issue requiring blood transfusion. Apart from this, blood transfusion is used during severe blood loss due to accidents, childbirth, and surgeries. All of these things also happen in hospitals, which is why a continuous high demand for blood occurs.

Recent Developments

  • In April 2024, the BD Vacutainer® UltraTouchTM Push Button Blood Collection Set was recently introduced in India by BD (Becton, Dickinson, and Company) with the goal of reducing patient pain and suffering and facilitating single-prick success during the blood collection procedure.
  • In February 2024, patients with sickle cell disease in England will soon have access to better care nearer to their homes thanks to an announced £1.5 million investment in 25 red blood cell exchange machines.

Top Companies in the Blood Product Market

  • KM Biologics
  • Nanyue Bio
  • Nordisk
  • Weiguang Bio
  • Yuanda Shuyang
  • Boya Bio
  • F. Hoffmann-La Roche Ltd.
  • Shuanglin Bio
  • Bio-Rad Laboratories Inc.
  • Tiantan Bio
  • Hualan Bio
  • CBPO
  • LFB Group
  • Merck & Co, Inc.
  • RAAS
  • Biotest
  • Octapharma
  • Haemonetics Corporation
  • Grifols
  • Kedrion
  • CSL
  • Ortho Clinical Diagnostics
  • Takeda
  • BPL

Segments Covered in the Report

By Product Type

  • Red Blood Cells (RBCs)
  • White Blood Cells (WBCs)
  • Fresh Frozen Plasma (FFP)
  • Platelets

By End-use

  • Blood Station
  • Hospital
  • Other

By Region

  • North America
    • U.S.
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Thailand
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • UAE
    • Saudi Arabia
    • Kuwait
  • Insight Code: 5292
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: October 2024
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

Meet the Team

Shivani Zoting is a healthcare market research expert with 2+ years of experience, specializing in analyzing trends, identifying growth opportunities, and providing actionable insights for businesses across healthcare sectors.

Learn more about Shivani Zoting

Aditi Shivarkar, with 14+ years of healthcare market research experience, ensures the accuracy, clarity, and relevance of reports. Her expertise helps businesses make informed decisions and stay competitive in healthcare sectors.

Learn more about Aditi Shivarkar

Related Reports

FAQ's

Red blood cells should be stored between +2°C and +6°C, platelets and leucocytes between +20°C and +24°C, and plasma products below -18°C, according to established standards. Additionally, if cross-matched units are available, additional equipment is needed to keep them safe.

The standards set out by the World Health Organization (WHO) for the collection, handling, and quality assurance of blood, blood components, and plasma derivatives.

Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC. Red Cross Blood Donation.